Moving beyond the syndrome: how can acute kidney injury phenotypes help?

The purpose of this review is to describe recent and important updates in acute kidney injury (AKI) phenotyping that help us to move beyond the clinical syndrome of AKI.

Recent studies reinforce the utility of damage biomarker positivity in AKI classification and have found that biomarker positivity (specifically NGAL) adds prognostic information regardless of classification of the AKI according to RIFLE or KDIGO criteria, and regardless of cut-off selection methodology. Novel methodologies for identifying AKI phenotypes and subphenotypes are currently being developed and integrated subclassification approaches e.g. combining biomarker and transcriptomic approaches, have been found to be more informative than using a single approach alone to identify AKI phenotypes. Consortiums have developed in partnership between academia and industry to identify consensus endotypes for critically ill adults and children.

There are prognostic and treatment benefits to AKI phenotyping and subphenotyping which allow us to provide a customized approach to AKI care. Challenges currently exist to implementation of AKI phenotyping at the bedside but ongoing projects are already seeking solutions for feasible bedside identification of subphenotypes using machine-learning or point-of-care biomarker assays. Future research in this area will focus on the ability to recognize and link endotypes, subphenotypes and phenotypes in AKI.